Update in New Medications for Primary Care
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Each year, the FDA approves dozens of new drugs for use in clinical practice. Clinicians must wade through a staggering amount of evidence to determine which drugs will be important new additions to their practice. Many of the new drugs relate to specialty practices, such as chemotherapeutic agents and immune-based therapies. A fraction of the newly approved drugs are potentially relevant for primary care clinicians. Most of these drugs are “me too” drugs that are a new drug within an existing class of medications. For example, the FDA may approve a new beta-blocker or a new proton-pump inhibitor. When these types of new drugs are as effective and safe as existing drugs, they are welcome primarily when their cost to patients and health plans is lower than that of currently available drugs.
However, a small number of drugs each year are novel and relevant for primary care practice. These are drugs that work through a completely new mechanism compared to existing therapies and have the po ...
- US Food and Drug Administration. Center for Drug Evaluation and Research. Drugs @ FDA. FDA approved drug products. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed: September 23, 2008.
- Department of Health and Human Services. Centers for Disease Control and Prevention. Smoking and tobacco use. Fast facts. Available at: http://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm Accessed: September 23, 2008.
- Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55. CrossRef
- Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63. CrossRef
- Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64–71. CrossRef
- Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised, open-label trial. Thorax 2008.
- US Food and Drug Administration CfDEaR. Early communication about an ongoing safety review of varenicline (marketed as Chanitx. Available at: Available at http://www.fda.gov/cder/drug/early_comm/varenicline.htm. Accessed: September 23, 2008.
- US Food and Drug Administration CfDEaR. Information for healthcare professionals on varenicline (marketed as Chantix). Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/vareniclineHCP.htm. Accessed: September 23, 2008.
- Cherry D, Woodwell D, Rechtsteiner E. National Ambulatory Medical Care Survey: 2005 summary. Advanced data from vital and health statistics; no.387: National Center for Health Statistics; 2007.
- Ostchega Y, Yoon S, Hughes J, Louis T. Hypertension awareness, treatment, and control–continued disparities in adults: United States, 2005–2006. NCHS data brief no. 3. Hyattsville, MD: National Center for Health Statistics; 2008.
- Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012–8. CrossRef
- Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157–63. CrossRef
- Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11–20. CrossRef
- Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221–9. CrossRef
- Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217–26. CrossRef
- Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72. CrossRef
- National Center for Health Statistics. Health, United States, 2007. With chartbook on trends in the health of Americans. Hyattsville, MD.; 2007.
- Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20. CrossRef
- Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632–7. CrossRef
- Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556–68. CrossRef
- American Diabetes Association. Standards of medical care in diabetes- 2007. Diabetes Care. 2007;30(suppl 1):S4–41. CrossRef
- Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638–43. CrossRef
- Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206. CrossRef
- Hoogwerf B. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus. Cleve Clin J Med. 2006;73:477–84. CrossRef
- Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705. CrossRef
- Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. 2007;335:87. CrossRef
- Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27:397–412. CrossRef
- Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–76.
- Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–55. CrossRef
- Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2007;147:633–8.
- Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003;290:2301–12. CrossRef
- Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–55.
- Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89. CrossRef
- Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006;173:1390–413. CrossRef
- Foglio K, Bianchi L, Bruletti G, Battista L, Pagani M, Ambrosino N. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J. 1999;13:125–32. CrossRef
- Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64:1279–83. CrossRef
- Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19. CrossRef
- Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–45. CrossRef
- Calhoun DA. Is there an unrecognized epidemic of primary aldosteronism? Pro Hypertension. 2007;50:447–53. discussion 447–53. CrossRef
- Kaplan NM. Is there an unrecognized epidemic of primary aldosteronism? Con Hypertension. 2007;50:454–8. discussion 454–8. CrossRef
- Hermida RC, Ayala DE, Calvo C, et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension. 2005;46:1053–9. CrossRef
- Update in New Medications for Primary Care
Journal of General Internal Medicine
Volume 24, Issue 1 , pp 111-117
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Shapiro 621D, 330 Brookline Ave., Boston, MA, USA
- 3. Harvard Medical School, Boston, MA, USA
- 2. Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital, Boston, MA, USA